ReviewClinical, cosmetic and investigational dermatology2026
Therapeutic Potential of Isoniazid in Inflammatory Skin Diseases: A Review.
Review in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Isoniazid (INH), a well-established anti-tuberculosis agent, has recently gained increasing interest because of its anti-inflammatory and immunomodulatory properties. This review is intended to summarize the mechanistic basis of INH in inflammatory skin disorders and to assess its potential clinical applicability. However, most evidence discussed here derives from preclinical studies and remains largely hypothesis-generating. Materials and Methods: A literature search was performed in the CNKI and PubMed databases. Results: The anti-inflammatory activity of INH is mediated through several pathways, including regulation of the ROS-PPARγ-NF-κB/AP-1 axis, suppression of NLRP3 inflammasome activation, and modulation of the Th1/Th2 balance. Therapeutic potential has been observed in conditions such as atopic dermatitis, psoriasis, urticaria, and rosacea, particularly among patients with latent tuberculosis infection or those undergoing biologic therapy, supporting its dual "anti-inflammatory-antituberculosis" value. Conclusion: INH demonstrates a multi-target mode of action and distinct dual clinical advantages in the management of inflammatory skin diseases, rendering it especially relevant for resource-constrained settings and selected patient populations. Additional clinical investigations remain necessary to determine the optimal treatment strategy and to further establish its safety profile. However, clinical evidence remains limited and further prospective studies are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.